Every 10-Q that Gilead Sciences Inc (GILD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow GILD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GILD filings page.
Gilead Sciences reported Q2 2026 total revenues of $7,803 million, up 10% year over year, and first-half revenues of $14,763 million, up 7%. Growth was led by HIV medicines including Biktarvy and Descovy, oncology drug Trodelvy, and liver disease product Livdelzi, partly offset by sharply lower COVID-19 therapy Veklury and weaker cell therapy and HCV sales.
Despite revenue growth, Gilead posted a Q2 net loss of $10,496 million and a first-half net loss of $8,475 million, driven mainly by $11,183 million of acquired in-process R&D expenses for the Arcellx, Tubulis and Ouro Medicines deals and a $1,750 million impairment on a Trodelvy NSCLC asset. Operating cash flow remained strong at $6,117 million for the first half, while total debt, net, rose to $26,246 million. Regulatory highlights included FDA accelerated approval of Hepcludex for hepatitis delta and expanded approvals for Trodelvy, alongside full FDA approval for Tecartus and multiple late-stage oncology and HIV filings.
Gilead Sciences reported higher profit and revenue for the quarter ended March 31, 2026. Total revenues rose to $6.96 billion from $6.67 billion, driven mainly by 10% growth in HIV product sales to $5.03 billion and 37% growth in Trodelvy oncology sales to $402 million, partly offset by a 52% decline in Veklury COVID-19 sales to $144 million and lower cell therapy revenue.
Net income increased to $2.02 billion from $1.32 billion, and diluted earnings per share rose to $1.61 from $1.04, helped by higher product sales, lower acquired in‑process R&D expenses and net unrealized gains on equity securities. Operating cash flow strengthened to $2.54 billion, and the company ended the quarter with $7.63 billion in cash and cash equivalents.
Looking ahead, Gilead expects a large non‑recurring charge. Management plans to record about $11.5 billion of acquired in‑process R&D expense in the second quarter of 2026 tied to recent Arcellx, Tubulis and Ouro transactions, and indicates this will result in a net loss for both the second quarter and full year 2026 despite solid underlying operations.
Gilead Sciences (GILD) filed its Q3 2025 10‑Q, reporting total revenue of $7.77 billion, up from $7.55 billion a year ago, and diluted EPS of $2.43 versus $1.00. Net income rose to $3.05 billion from $1.25 billion as operating income improved to $3.33 billion, reflecting lower charges versus last year and higher royalty and contract revenue.
Product sales were $7.35 billion (slightly below $7.52 billion last year). HIV remained the core driver at $5.28 billion, led by Biktarvy at $3.69 billion. Liver Disease rose to $819 million, while Veklury declined to $277 million. Oncology product sales were $788 million, with Cell Therapy at $432 million and Trodelvy at $357 million. The company recognized $400 million of previously constrained revenue tied to a sale of certain intellectual property, lifting royalty/contract revenue to $424 million. Cash and equivalents were $7.33 billion; operating cash flow for the nine months was $6.69 billion. Shares outstanding were 1,240,679,623 as of October 31, 2025.